Tacalyx
Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
$31—46m (Dealroom.co estimates Jun 2024.)
Company register number HRB 32607 P (Potsdam)
Berlin Germany (HQ)
Authorizing premium user...